Treatment of mucocutaneous manifestations in Behcet's disease with anakinra: a pilot open-label study.

ABSTRACT:

Background

The effect of IL-1 blocking therapy on mucocutaneous manifestations of Behçet's disease is incompletely understood.

Methods

Six patients with Behçet's disease and ongoing oral/genital ulcers for ≥1 month were enrolled into an adaptive, two-phase clinical trial and included in the analysis. Study duration was 6 months with extension up to 16 months. All were treated non-blinded with anakinra 100 mg subcutaneous daily with the option to escalate the dose to 200 mg in partial responders after 1 month and 300 mg after 6 months. Patients recorded the number and severity of ulcers in daily diaries. The primary outcome was remission defined as no ulcers on physical exam for two consecutive monthly visits between months 3 and 6. Secondary outcomes included the number and

SUBMITTER: Grayson PC 

PROVIDER: S-EPMC5364674 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature